The researchers now plan to incorporate their new tool into a drug development program, leading to early clinical trials.

A new study in Human Gene Therapy describes a machine learning (ML) model that can be used as a surrogate for laborious in ...

Latus Bio Inc. (Latus), a biotechnology company pioneering advances in AAV gene therapy, has announced upcoming oral and ...

The company’s exhibitions will be focused in the areas of its pipeline, proprietary capsid engineering, and manufacturing.

8 Humoral and cellular responses to the AAV capsid and factor IX were measured periodically after treatment with the use of a neutralizing antibody assay and an interferon-γ enzyme-linked ...

Wednesday, May 14, 2025, 5:30 p.m. – 7:00 p.m. CT Voyager’s TRACER™ (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) capsid discovery platform is a broadly applicable ...

Agreement grants Lilly rights to employ Sangamo’s novel proprietary capsid, STAC-BBB, for up to five potential disease targets Sangamo to receive an $18 million upfront license fee and is ...

One abstract accepted as platform presentation in prestigious Presidential Symposium, demonstrating potent combination of epigenetic regulation and capsid delivery technology in treating prion ...

These presentations showcase progress toward advancing Latus’ novel AAV capsid variants - AAV-DB-3 and AAV-Ep+ - to address Huntington’s Disease and CLN2 Batten Disease, respectively.